Company / Interest Expense
Royalty Pharma plc Interest Expense History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$187.2M
FY2023
5-year range
$157.1M / $268.6M
FY2019-FY2023
Trend
+19.2%
vs FY2022
Sector context
#10 of 44
Health Care
What the data says
Royalty Pharma plc's interest expense of $187M is higher than 77% of companies in the Health Care sector (FY2023). Interest Expense returned to growth in FY2023 after 2 years of decline, reaching $187M.
Based on SEC 10-K filings.
$187M in FY2023 with a 5-year CAGR of -7.7%. Top quartile in the Health Care sector.
Improved from $269M to $187M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -12.6%
- 5-Year CAGR
- -7.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 44This company $187.2M Sector average $291.0M
▼
-35.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -7.7%, indicating a declining trend.
- In FY2023, interest expense increased 19.2% year-over-year.
- Ranks #10 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- Strong profit margin: 38.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $187.2M | +19.2% |
| FY2022 | $157.1M | -41.5% |
| FY2021 | $268.6M | -4.1% |
| FY2020 | $280.0M | +4.2% |
| FY2019 | $268.6M | -4.1% |
| FY2018 | $280.0M | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026